MedTrace Logo

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

NCT03938922 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-03-01

No results posted yet for this study

Summary

This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.

Conditions

Interventions

DRUG

Active Investigational Treatment ENT-01

ENT-01 will be administered in tablet form, once daily. Other Names: ENT-01

Sponsors & Collaborators

  • Enterin Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Zasloff, MD, Ph.D · Enterin Inc.

  • Denise Barbut, MD, FRCP · Enterin Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2025-06-15
Completion
2025-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03938922 on ClinicalTrials.gov